Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397649323> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2397649323 endingPage "7" @default.
- W2397649323 startingPage "173" @default.
- W2397649323 abstract "The objective of this study was to determine whether alternative sunitinib schedules (AS) could prolong survival of patients with advanced renal cell carcinoma (RCC) compared to the traditional 4-weeks-on/2- weeks-off schedule (TS). Between August 2008 and December 2014, 58 patients with advanced RCC were treated with sunitinib. We retrospectively reviewed the records of the patients who received first-line sunitinib. The progression-free survival, overall survival, relative dose intensity and toxicity in the AS and TS groups were compared. A total of 38 patients were included in the analysis. AS was used for 22 patients who started to receive sunitinib beginning in December 2012. For these patients, sunitinib was administered with a 2-weeks-on/1-week-off, 2-weeks-on/2-weeks-off or 2-weeks-on/3-weeks-off schedule according to the adverse events and clinical characteristics of each patient. The median progression-free survival was 5 months (95% CI: 3-7) for TS compared to 12 months (95% CI: 7-17) for AS (p＝0.0020). The median overall survival was 17 months (95% CI: 10-20) for TS compared to 57 months (95% CI: 25-57) for AS (p＝0.0006). There was no significant difference between the TS and AS groups (64% versus 71%). The incidence of Grade ≥3 thrombocytopenia in the AS group was smaller than that in the TS group (44% versus 27%). Treatment with sunitinib using AS may provide a better outcome than that with TS. Prospective, randomized trials should be conducted to confirm this speculation." @default.
- W2397649323 created "2016-06-24" @default.
- W2397649323 creator A5003368584 @default.
- W2397649323 creator A5037711521 @default.
- W2397649323 creator A5039892623 @default.
- W2397649323 creator A5043005697 @default.
- W2397649323 creator A5083918280 @default.
- W2397649323 date "2016-04-01" @default.
- W2397649323 modified "2023-10-16" @default.
- W2397649323 title "[Dosing Schedules and Outcomes in Patients Treated with First-Line Sunitinib for Advanced Renal Cell Carcinoma]." @default.
- W2397649323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27217010" @default.
- W2397649323 hasPublicationYear "2016" @default.
- W2397649323 type Work @default.
- W2397649323 sameAs 2397649323 @default.
- W2397649323 citedByCount "0" @default.
- W2397649323 crossrefType "journal-article" @default.
- W2397649323 hasAuthorship W2397649323A5003368584 @default.
- W2397649323 hasAuthorship W2397649323A5037711521 @default.
- W2397649323 hasAuthorship W2397649323A5039892623 @default.
- W2397649323 hasAuthorship W2397649323A5043005697 @default.
- W2397649323 hasAuthorship W2397649323A5083918280 @default.
- W2397649323 hasConcept C120665830 @default.
- W2397649323 hasConcept C121332964 @default.
- W2397649323 hasConcept C126322002 @default.
- W2397649323 hasConcept C126894567 @default.
- W2397649323 hasConcept C141071460 @default.
- W2397649323 hasConcept C197934379 @default.
- W2397649323 hasConcept C2777288759 @default.
- W2397649323 hasConcept C2777472916 @default.
- W2397649323 hasConcept C2779490328 @default.
- W2397649323 hasConcept C29730261 @default.
- W2397649323 hasConcept C535046627 @default.
- W2397649323 hasConcept C61511704 @default.
- W2397649323 hasConcept C71924100 @default.
- W2397649323 hasConceptScore W2397649323C120665830 @default.
- W2397649323 hasConceptScore W2397649323C121332964 @default.
- W2397649323 hasConceptScore W2397649323C126322002 @default.
- W2397649323 hasConceptScore W2397649323C126894567 @default.
- W2397649323 hasConceptScore W2397649323C141071460 @default.
- W2397649323 hasConceptScore W2397649323C197934379 @default.
- W2397649323 hasConceptScore W2397649323C2777288759 @default.
- W2397649323 hasConceptScore W2397649323C2777472916 @default.
- W2397649323 hasConceptScore W2397649323C2779490328 @default.
- W2397649323 hasConceptScore W2397649323C29730261 @default.
- W2397649323 hasConceptScore W2397649323C535046627 @default.
- W2397649323 hasConceptScore W2397649323C61511704 @default.
- W2397649323 hasConceptScore W2397649323C71924100 @default.
- W2397649323 hasIssue "4" @default.
- W2397649323 hasLocation W23976493231 @default.
- W2397649323 hasOpenAccess W2397649323 @default.
- W2397649323 hasPrimaryLocation W23976493231 @default.
- W2397649323 hasRelatedWork W2072245035 @default.
- W2397649323 hasRelatedWork W2081371466 @default.
- W2397649323 hasRelatedWork W2096517981 @default.
- W2397649323 hasRelatedWork W2169881885 @default.
- W2397649323 hasRelatedWork W2322617799 @default.
- W2397649323 hasRelatedWork W2544140097 @default.
- W2397649323 hasRelatedWork W2590524093 @default.
- W2397649323 hasRelatedWork W3151554875 @default.
- W2397649323 hasRelatedWork W4205243027 @default.
- W2397649323 hasRelatedWork W4205299447 @default.
- W2397649323 hasVolume "62" @default.
- W2397649323 isParatext "false" @default.
- W2397649323 isRetracted "false" @default.
- W2397649323 magId "2397649323" @default.
- W2397649323 workType "article" @default.